Active substances set

Search phrase: venetoclax

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Chronic lymphoid leukemia

Venetoclax	Venetoclax in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). Venetoclax in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy. Venetoclax monotherapy is indicated for the treatment of CLL: - in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor, or - in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.	FULL REIMBURSEMENT ESMO

Acute myeloid leukemia

Venetoclax	Venetoclax in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.	REIMBURSEMENT WITH RESTRICTIONS ESMO